14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.58 $5.85 Friday, 3rd May 2024 CTMX stock ended at $4.43. This is 1.56% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 14.22% from a day low at $4.43 to a day high of $5.06.
90 days $1.38 $5.85
52 weeks $1.04 $5.85

Historical CytomX Therapeutics prices

Date Open High Low Close Volume
Feb 23, 2023 $2.25 $2.28 $2.18 $2.23 846 702
Feb 22, 2023 $2.28 $2.29 $2.23 $2.25 449 511
Feb 21, 2023 $2.30 $2.35 $2.24 $2.26 609 791
Feb 17, 2023 $2.25 $2.37 $2.24 $2.36 670 143
Feb 16, 2023 $2.33 $2.36 $2.25 $2.28 1 460 764
Feb 15, 2023 $2.39 $2.42 $2.30 $2.32 1 102 211
Feb 14, 2023 $2.50 $2.50 $2.36 $2.42 2 124 072
Feb 13, 2023 $2.54 $2.54 $2.43 $2.47 1 147 684
Feb 10, 2023 $2.50 $2.57 $2.45 $2.54 1 125 407
Feb 09, 2023 $2.60 $2.63 $2.47 $2.50 1 644 450
Feb 08, 2023 $2.77 $2.77 $2.60 $2.60 1 498 380
Feb 07, 2023 $2.83 $2.83 $2.70 $2.75 1 195 693
Feb 06, 2023 $2.64 $2.85 $2.62 $2.84 1 973 264
Feb 03, 2023 $2.60 $2.71 $2.60 $2.65 865 334
Feb 02, 2023 $2.70 $2.75 $2.56 $2.59 1 522 072
Feb 01, 2023 $2.69 $2.71 $2.61 $2.68 994 909
Jan 31, 2023 $2.63 $2.74 $2.63 $2.70 952 914
Jan 30, 2023 $2.74 $2.75 $2.64 $2.68 1 966 148
Jan 27, 2023 $2.75 $2.85 $2.73 $2.77 1 365 547
Jan 26, 2023 $2.74 $2.92 $2.69 $2.78 3 658 322
Jan 25, 2023 $2.74 $2.74 $2.56 $2.62 1 358 008
Jan 24, 2023 $2.72 $2.78 $2.64 $2.75 1 622 367
Jan 23, 2023 $2.57 $2.80 $2.49 $2.73 3 304 190
Jan 20, 2023 $2.50 $2.54 $2.45 $2.52 2 530 391
Jan 19, 2023 $2.55 $2.59 $2.46 $2.50 2 015 748
Click to get the best stock tips daily for free!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT